Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 13/20 | 0.55 |
| ▸ | CNR1 | P21554 | 11/20 | 0.55 |
| ▸ | DRD3 | P35462 | 1/20 | 0.53 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.53 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.53 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.53 |
| ▸ | GLRA1 | P23415 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15506419 | 1.00 | CNR2 (0.55) | CNR2CNR1DRD3NR1I2ADORA3 | |
| SCHEMBL17694493 | 0.89 | CNR2 (0.60) | CNR2CNR1DRD3GLRA1 | |
| SCHEMBL31545709 | 0.89 | CNR2 (0.60) | CNR2CNR1DRD3GLRA1 | |
| SCHEMBL17694494 | 0.88 | CNR2 (0.55) | CNR2CNR1DRD3NR1I2ADORA3 | |
| SCHEMBL15516023 | 0.87 | CNR2 (0.56) | CNR2CNR1DRD3NR1I2ADORA3 | |
| SCHEMBL23197913 | 0.87 | CNR2 (0.50) | CNR2CNR1DRD3NR1I2ADORA3 | |
| SCHEMBL21137738 | 0.86 | CNR2 (0.60) | CNR2CNR1GLRA1 | |
| SCHEMBL17686855 | 0.85 | DRD3 (0.53) | CNR2CNR1DRD3 | |
| SCHEMBL23197910 | 0.79 | CNR2 (0.51) | CNR2CNR1DRD3NR1I2ADORA3 | |
| SCHEMBL15506421 | 0.78 | CNR2 (0.48) | CNR2CNR1DRD3NR1I2ADORA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11964956-B2 | Cannabinergic compounds and uses thereof | NORTHEASTERN UNIVERSITY (US) | 2024-04-23 | — | — | US | disclosed |
| US-20210101878-A1 | Cannabinergic Compounds And Uses Thereof | NORTHEASTERN UNIVERSITY | 2021-04-08 | — | — | US | disclosed |
| US-20190185443-A1 | Novel Cannabinergic Compounds And Uses Thereof | NORTHEASTERN UNIVERSITY | 2019-06-20 | — | — | US | disclosed |
| WO-2014039042-A1 | NOVEL CANNABINERGIC COMPOUNDS AND USES THEREOF | NORTHEASTERN UNIVERSITY (US) | 2014-03-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11964956-B2 | Cannabinergic compounds and uses thereof | CNR2, CNR1, GPR18 | CNR2 1/4885CNR1 2/4885DRD3 870/4885 |
| US-20190185443-A1 | Novel Cannabinergic Compounds And Uses Thereof | CNR2, CNR1, GPR18 | CNR2 1/4885CNR1 2/4885DRD3 864/4885 |
| US-20210101878-A1 | Cannabinergic Compounds And Uses Thereof | CNR2, CNR1, GPR18 | CNR2 1/4885CNR1 2/4885DRD3 870/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.